Cediranib Maleate and Selumetinib Sulfate in Treating Patients With Solid Malignancies
Status:
Active, not recruiting
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial studies the side effects and best dose of cediranib maleate and
selumetinib sulfate in treating patients with solid malignancies. Cediranib maleate and
selumetinib may stop the growth of tumor cells by blocking some of the enzymes needed for
cell growth. Cediranib maleate may also stop the growth of tumor cells by blocking blood flow
to the tumor.